These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 39294027)

  • 1. Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4/6 Inhibitors.
    Kanjanapan Y; Anderson W; Smith M; Green J; Chalker E; Craft P
    Clin Breast Cancer; 2024 Aug; ():. PubMed ID: 39294027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy
    Slamon DJ; Fasching PA; Hurvitz S; Chia S; Crown J; Martín M; Barrios CH; Bardia A; Im SA; Yardley DA; Untch M; Huang CS; Stroyakovskiy D; Xu B; Moroose RL; Loi S; Visco F; Bee-Munteanu V; Afenjar K; Fresco R; Taran T; Chakravartty A; Zarate JP; Lteif A; Hortobagyi GN
    Ther Adv Med Oncol; 2023; 15():17588359231178125. PubMed ID: 37275963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
    Johnston SRD; Toi M; O'Shaughnessy J; Rastogi P; Campone M; Neven P; Huang CS; Huober J; Jaliffe GG; Cicin I; Tolaney SM; Goetz MP; Rugo HS; Senkus E; Testa L; Del Mastro L; Shimizu C; Wei R; Shahir A; Munoz M; San Antonio B; André V; Harbeck N; Martin M;
    Lancet Oncol; 2023 Jan; 24(1):77-90. PubMed ID: 36493792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of Surgery.
    Houvenaeghel G; Classe JM; Chauvet MP; Colombo PE; Jouve E; Reyal F; Daraï E; Rouzier R; Faure-Virelizier C; Gimbergues P; Coutant C; Mazouni C; Azuar AS; Martino M; Bouteille C; Cohen M; de Nonneville A
    Cancers (Basel); 2024 Sep; 16(19):. PubMed ID: 39409937
    [No Abstract]   [Full Text] [Related]  

  • 5. The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers.
    Schäffler H; Mergel F; Pfister K; Lukac S; Fink A; Veselinovic K; Rack B; Fink V; Leinert E; Dimpfl M; Englisch A; Tegeler CM; Seller A; Grischke EM; Hahn M; Volmer LL; Engler T; Frevert ML; Taran FA; Janni W; Brucker SY; Hartkopf AD; Dannehl D
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registry.
    Frevert ML; Dannehl D; Jansen L; Hermann S; Schäffler H; Huwer S; Janni W; Juhasz-Böss I; Hartkopf AD; Taran FA
    Arch Gynecol Obstet; 2024 Jun; 309(6):2811-2819. PubMed ID: 38472501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
    Johnston SRD; Harbeck N; Hegg R; Toi M; Martin M; Shao ZM; Zhang QY; Martinez Rodriguez JL; Campone M; Hamilton E; Sohn J; Guarneri V; Okada M; Boyle F; Neven P; Cortés J; Huober J; Wardley A; Tolaney SM; Cicin I; Smith IC; Frenzel M; Headley D; Wei R; San Antonio B; Hulstijn M; Cox J; O'Shaughnessy J; Rastogi P;
    J Clin Oncol; 2020 Dec; 38(34):3987-3998. PubMed ID: 32954927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Adjuvant Abemaciclib and Ribociclib in High-Risk Hormone Receptor-Positive Early Breast Cancer: An Indian Perspective.
    Sra MS; Sasi A; Batra A; Bakhshi S; Ganguly S
    JCO Glob Oncol; 2024 Jul; 10():e2300433. PubMed ID: 39024528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole.
    Fasching PA; Hack CC; Nabieva N; Maass N; Aktas B; Kümmel S; Thomssen C; Wolf C; Kolberg HC; Brucker C; Janni W; Dall P; Schneeweiss A; Marme F; Sütterlin MW; Ruebner M; Theuser AK; Kellner S; Hofmann NM; Böhm S; Almstedt K; Lück HJ; Schmatloch S; Kalder M; Uleer C; Jurhasz-Böss I; Hanf V; Jackisch C; Müller V; Rack B; Belleville E; Wallwiener D; Rody A; Rauh C; Bayer CM; Uhrig S; Goossens C; Huebner H; Brucker SY; Hein A; Fehm TN; Häberle L
    Eur J Cancer; 2024 Sep; 209():114239. PubMed ID: 39059184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting.
    Abdel-Razeq H; Sharaf B
    Drug Des Devel Ther; 2022; 16():727-735. PubMed ID: 35321498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
    Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
    Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.
    de Boniface J; Appelgren M; Szulkin R; Alkner S; Andersson Y; Bergkvist L; Frisell J; Gentilini OD; Kontos M; Kühn T; Lundstedt D; Offersen BV; Olofsson Bagge R; Reimer T; Sund M; Christiansen P; Rydén L; Filtenborg Tvedskov T;
    Lancet Oncol; 2024 Sep; 25(9):1222-1230. PubMed ID: 39121881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapies for HR+/HER2-breast cancer: Systematic review and network meta-analysis.
    Tong F; Lu Y; Ma HF; Shen J
    Heliyon; 2024 Jun; 10(11):e31583. PubMed ID: 38832268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors.
    Burne R; Balu S; Guérin A; Bungay R; Sin R; Paul ML
    J Med Econ; 2021; 24(1):806-815. PubMed ID: 34098827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.
    Martin M; Hegg R; Kim SB; Schenker M; Grecea D; Garcia-Saenz JA; Papazisis K; Ouyang Q; Lacko A; Oksuzoglu B; Reeves J; Okera M; Testa L; Shimizu C; Denduluri N; Adamchuk H; Dakhil S; Wei R; Forrester T; Fernandez MM; Zimmermann A; Headley D; Johnston SRD
    JAMA Oncol; 2022 Aug; 8(8):1190-1194. PubMed ID: 35653145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms.
    Haslam A; Ranganathan S; Prasad V; Olivier T
    Eur J Cancer; 2024 Aug; 207():114192. PubMed ID: 38959677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
    Harbeck N; Rastogi P; Martin M; Tolaney SM; Shao ZM; Fasching PA; Huang CS; Jaliffe GG; Tryakin A; Goetz MP; Rugo HS; Senkus E; Testa L; Andersson M; Tamura K; Del Mastro L; Steger GG; Kreipe H; Hegg R; Sohn J; Guarneri V; Cortés J; Hamilton E; André V; Wei R; Barriga S; Sherwood S; Forrester T; Munoz M; Shahir A; San Antonio B; Nabinger SC; Toi M; Johnston SRD; O'Shaughnessy J;
    Ann Oncol; 2021 Dec; 32(12):1571-1581. PubMed ID: 34656740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Cyclin-Dependent Kinase 4/6 in Metastatic Breast Cancer: Real-World Data From a Tertiary Care Institute in Eastern India.
    Das Majumdar SK; Barik SK; Pattanaik A; Das DK; Parida DK
    Cureus; 2024 Jan; 16(1):e52172. PubMed ID: 38344632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry.
    Martín M; Carrasco E; Rodríguez-Lescure Á; Andrés R; Servitja S; Antón A; Ruiz-Borrego M; Bermejo B; Guerrero Á; Ramos M; Santaballa A; Muñoz M; Cruz J; Lopez-Tarruella S; Chacón JI; Álvarez I; Martínez P; Miralles JJ; Polonio Ó; Jara C; Aguiar-Bujanda D
    Breast Cancer Res Treat; 2023 Sep; 201(2):151-159. PubMed ID: 37338729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+ HER2- Early Breast Cancer.
    Raheem F; Ofori H; Simpson L; Shah V
    Ann Pharmacother; 2022 Feb; ():10600280211073322. PubMed ID: 35135362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.